epitope mapping near the C-terminus of Evi-1 of human origin
recommended for detection of Evi-1 of mouse and human origin by WB, IP, IF and ELISA; also reactive with additional species, including equine and canine
blocking peptide, sc-8707 P
TransCruz reagent for Gel Supershift and ChIP applications, sc-8707 X, 200 µg/0.1 ml
Evi-1 Background Information The Evi-1 proto-oncogene contains two zinc finger domains, the second of which is essential for transactivation of the c-Fos promoter and for AP-1 activation. The first zinc finger domain binds to Smad3, suppressing its activity and inhibiting TGF∫ signaling. The t(3;21) (q26;q22) chromosomal translocation produces a chimeric transcription factor, AML-1/Evi-1, that appears to suppress the transactivation of AML-1, which is a stimulator of myeloid cell differentiation. Inappropriate Evi-1 gene expression in hemato-poietic cells has been shown to be associated with acute myelogenous leukemia (AML) and myelodysplastic syndromes.
Evi-1 (C-20)-R
Click on image to enlarge
Evi-1 (C-20)-R: sc-8707-R. Western blot analysis of Evi-1 expression in non-transfected: sc-117752 (A) and human Evi-1 transfected: sc-177200 (B) 293T whole cell lysates.
Evi-1 (C-20)-R: sc-8707-R. Western blot analysis of Evi-1 expression in non-transfected: sc-117752 (A) and human Evi-1 transfected: sc-177200 (B) 293T whole cell lysates.
Evi-1 (C-20)-R: sc-8707-R. Western blot analysis of Evi-1 expression in 293T whole cell lysate.
